Primate lentivirus antigenic compositions
AssigneePresident and Fellows of Harvard College
InventorRonald C. Desrosiers
Life of this patent
Estimating the term…
Abstract
Molecular clones of primate lentiviruses that harbor an engineered non-revertible null mutation in the nef gene and which may further include a non-revertible null mutation in one or more non-essential genetic elements, vif, vpr, vpx, vpu, Negative Regulatory Element, nuclear factor .kappa.B-binding element, or Sp1 binding element sequences are disclosed. Intact viruses containing such mutant genomes are also disclosed. These infectious, nonpathogenic viruses are capable of eliciting a protective host immune response and, thus, are useful as a vaccine that protects against AIDS in human subjects.
Claims33
An antigenic composition comprising isolated primate lentivirus whose genome contains an engineered non-revertible null mutation in the nef gene, or an infectious DNA clone thereof, in a pharmaceutically acceptable carrier.
A method of producing an antigenic composition comprising:
- transfecting cultured primate cells with primate lentiviral nucleic acid containing an engineered non-revertible null mutation of the nef gene,
- isolating lentivirus whose genome contains said mutation of the nef gene, and
- compounding said virus into a pharmaceutically acceptable antigenic compositions.
Dependencies are inferred from the claim text.